ARTICLE
23 March 2018

Highlights – Healthcare Life Sciences And Pharmaceuticals

P
PLMJ

Contributor

PLMJ is a law firm based in Portugal that combines a full service with bespoke legal craftsmanship. For more than 50 years, the firm has taken an innovative and creative approach to produced tailor-made solutions to effectively defend the interests of its clients. The firm supports its clients in all areas of the law, often with multidisciplinary teams, and always acting as a business partner in the most strategic decision-making processes.
Recommendation of the Portuguese Parliament no. 33/2018 2 February - The Portuguese Parliament recommends that the Government ...
Portugal Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

I. LEGISLATION

Recommendation of the Portuguese Parliament no. 33/2018 2 February - The Portuguese Parliament recommends that the Government goes ahead with a set of evaluations relating to the health impacts of cannabis consumption and the clinical advantages of its use for therapeutic purposes.

Decree-law no. 13/2018 of 26 February - Establishes the legal rules on postgraduate medical training, called medical internship, and has identified the general principles that the processing question must follow.

Recommendation of the Portuguese Parliament no. 55/2018 of 27 February - Recommends that the Government should bring more speed and efficiency to the mechanisms for evaluating devices and equipment to control and treat Diabetes Mellitus.

II. INFARMED, I.P.

01/01/2018 - Publication of the List of Medicines with Expiring Co-Pay - The Board of INFARMED has published the definitive list of medicines for which it has decided the co-pay should expire for not being sold in the period of 2018, by a decision of the Board of INFARMED, I.P., by Circular no. 106/CD of 7 July 2010.

Resolution no. 13/CD/2018 of the Board of Infarmed of 8 February 2018 - Updates the list of Homogenous Groups and unit reference prices to be in force in the first quarter of 2018, in the context of the Reference Prices System.

14/02/2018 - National Commission of Pharmacy and Therapeutics - The Commission has published its guidelines on the use of biosimilar medicines and the change of reference biological medicines for biosimilar medicines.

III. EUROPEAN MEDICINESAGENCY

28/02/2018 - The European Medicines Agency has reviewed the guidelines for clinical studies on medicines destined to treat Alzheimer's. The documen governs the development of medicines for all stages of the disease.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More